Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials

This article reviews the growing body of evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in treating various conditions beyond type 2 diabetes, such as chronic kidney disease, metabolic liver disease, and Alzheimer's disease. GLP-1 RAs have been shown to help manage type 2 diabetes, promote weight